Table 3:
Unadjusted and adjusted association between randomized aspirin dose and cumulative incidence of clinical endpoints in patients with and without PAD, with interaction between PAD status and dose
| PAD | No PAD | ||||||||
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| Clinical endpoint | 81 mg (%) | 325 mg (%) | Undadjusted HR (95% CI) | Adjusted HR (95% CI) | 81 mg (%) | 325 mg (%) | Undadjusted HR (95% CI) | Adjusted HR (95% CI) | Interaction p value |
|
| |||||||||
| Death, MI, Stroke | 247 (13.68%) | 245 (13.84%) | 1.05 (0.88–1.25) | 1.06 (0.88– 1.27) | 324 (5.25%) | 308 (5.38%) | 1.02 (0.87–1.19) | 1.04 (0.88– 1.22) | 0.883 |
|
| |||||||||
| All-cause mortality | 139 (7.25%) | 156 (7.84%) | 0.94 (0.75–1.18) | 0.99 (0.78– 1.26) | 170 (2.77%) | 192 (3.27%) | 0.86 (0.80–1.05) | 0.86 (0.69– 1.06) | 0.393 |
| Major bleeding | 27 (1.53%) | 17 (0.80%) | 1.66 (0.90, 3.04) | 1.55 (0.84, 2.87) | 24 (0.33%) | 26 (0.54%) | 0.89 (0.51, 1.56) | 1.03 (0.58, 1.86) | 0.348 |
Cumulative Incidence is reported at 26.2 months from randomization
Abbreviations: MI: myocardial infarction; PAD: peripheral artery disease